Aperio Group’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | $126M | Sell |
746,049
-34,415
| -4% | -$5.14M | 0.37% | 45 |
|
|
2020
Q3 | $116M | Sell |
780,464
-26,431
| -3% | -$4.09M | 0.39% | 44 |
|
|
2020
Q2 | $132M | Buy |
806,895
+11,452
| +1% | +$1.76M | 0.49% | 35 |
|
|
2020
Q1 | $110M | Buy |
795,443
+121,259
| +18% | +$16.7M | 0.49% | 34 |
|
|
2019
Q4 | $88.6M | Sell |
674,184
-2,113
| -0.3% | -$245K | 0.32% | 54 |
|
|
2019
Q3 | $75.6M | Sell |
676,297
-5,875
| -0.9% | -$654K | 0.3% | 57 |
|
|
2019
Q2 | $75.6M | Sell |
682,172
-19,149
| -3% | -$2.25M | 0.31% | 56 |
|
|
2019
Q1 | $91M | Buy |
701,321
+76,842
| +12% | +$9.34M | 0.39% | 47 |
|
|
2018
Q4 | $72.3M | Buy |
624,479
+44,871
| +8% | +$5.01M | 0.36% | 50 |
|
|
2018
Q3 | $62.2M | Buy |
579,608
+19,269
| +3% | +$1.93M | 0.27% | 71 |
|
|
2018
Q2 | $47.8M | Buy |
560,339
+35,588
| +7% | +$2.92M | 0.23% | 90 |
|
|
2018
Q1 | $40.6M | Sell |
524,751
-53,697
| -9% | -$4.32M | 0.2% | 106 |
|
|
2017
Q4 | $48.9M | Buy |
578,448
+53,330
| +10% | +$4.54M | 0.25% | 77 |
|
|
2017
Q3 | $44.9M | Buy |
525,118
+2,987
| +0.6% | +$245K | 0.25% | 82 |
|
|
2017
Q2 | $43M | Buy |
522,131
+33,765
| +7% | +$2.75M | 0.26% | 79 |
|
|
2017
Q1 | $41.1M | Buy |
488,366
+34,543
| +8% | +$2.77M | 0.28% | 70 |
|
|
2016
Q4 | $33.4M | Sell |
453,823
-113,307
| -20% | -$8.44M | 0.26% | 83 |
|
|
2016
Q3 | $45.5M | Buy |
567,130
+81,355
| +17% | +$6.51M | 0.33% | 60 |
|
|
2016
Q2 | $38.3M | Buy |
485,775
+2,420
| +0.5% | +$182K | 0.3% | 72 |
|
|
2016
Q1 | $34.8M | Sell |
483,355
-18,528
| -4% | -$1.4M | 0.3% | 66 |
|
|
2015
Q4 | $42.3M | Buy |
501,883
+31,000
| +7% | +$2.57M | 0.39% | 49 |
|
|
2015
Q3 | $39.4M | Buy |
470,883
+61,780
| +15% | +$5.22M | 0.4% | 45 |
|
|
2015
Q2 | $34.2M | Buy |
409,103
+40,111
| +11% | +$3.06M | 0.35% | 56 |
|
|
2015
Q1 | $26.8M | Buy |
368,992
+52,107
| +16% | +$3.71M | 0.3% | 71 |
|
|
2014
Q4 | $21.9M | Buy |
316,885
+42,442
| +15% | +$2.86M | 0.27% | 83 |
|
|
2014
Q3 | $17.8M | Buy |
274,443
+19,613
| +8% | +$1.24M | 0.24% | 95 |
|
|
2014
Q2 | $15.8M | Buy |
254,830
+12,213
| +5% | +$729K | 0.23% | 103 |
|
|
2014
Q1 | $14.3M | Buy |
+242,617
| New | +$13.5M | 0.2% | 110 |
|
|
2013
Q4 | – | Sell |
-227,403
| Closed | -$11.4M | – | 133 |
|
|
2013
Q3 | $11.4M | Buy |
227,403
+34,164
| +18% | +$1.79M | 0.22% | 96 |
|
|
2013
Q2 | $9.49M | Buy |
+193,239
| New | +$10.5M | 0.23% | 91 |
|
Other funds holding LLY
Aperio Group's LLY Position: Q4 2020 in Review
Aperio Group reduced its Eli Lilly (LLY) stake by 4.4% in Q4 2020, selling an estimated $5.14M and leaving 746,049 shares worth $126M. The position accounts for 0.37% of the portfolio, ranked #45.
Aperio Group first reported a position in LLY in Q2 2013 and has held it in 30 quarters since. The position peaked at $132M in Q2 2020. 1,887 funds tracked by Wall St. Rank hold LLY as of Q4 2020.
- Aperio Group held 746,049 shares of Eli Lilly worth $126M as of Q4 2020.
- Aperio Group sold 34,415 Eli Lilly shares in Q4 2020, an estimated $5.14M.
- Eli Lilly made up 0.37% of Aperio Group's portfolio in Q4 2020, its #45 holding.
- Aperio Group first reported a position in Eli Lilly in Q2 2013 and has held it in 30 quarters since.
- Aperio Group's Eli Lilly position peaked at $132M in Q2 2020.
- 1,887 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2020.
Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.